ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

follitropin delta

Also written as “Follitropin delta”, “FE 999049” and “Follitropin Delta (FE 999049)”.

Its studies are mostly in Infertility · Infertility, Female, led by 3 companies.

Drug pageFollitropin delta: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 16, 201318 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ferring Pharmaceuticalsits history only150 open or runningphase 3since Aug 16, 2013Aug 30, 2011none ahead
Clinique Ovoits history only21 open or runningphase 2since Jan 30, 2019Jan 30, 2019none ahead
Dr François Bissonnette10 open or runningno phasesince Mar 8, 2018Mar 8, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr François Bissonnette only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2018First study: no phase study in Fertility DisordersFirst studyNCT03483545 · 160 enrolled · Canada

TargetBeta

FSHR →read by rule
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule

Other programs on FSHR

ProgramCompanyFurthest phaseStudies
follitropin alfaruleMerck KGaA, Darmstadt, Germanyphase 426
Follicle Stimulating Hormoneruleglycotope-gmbhphase 46

Studies

The one study Dr François Bissonnette leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03483545Fertility Disorders · Canada–CompletedJul 31, 2019160

How it is read

Names in the registry

  • “Follitropin delta”, 5 entries
  • “FE 999049”, 4 entries
  • “Follitropin Delta (FE 999049)”, 3 entries
  • “Combination therapy : Follitropin delta and HP-hMG”, 1 entry
  • “REKOVELLE (Follitropin Delta)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.